Evidence map›Paper›PMID 34594031›Full record

ArticleNature methods2021

Systematic investigation of cytokine signaling activity at the tissue and single-cell levels.

Peng Jiang, Yu Zhang, Beibei Ru, Yuan Yang, Trang Vu, Rohit Paul, Amer Mirza, Grégoire Altan-Bonnet, Lingrui Liu, Eytan Ruppin and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Nature methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 245 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Peng Jiang *Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. peng.jiang@nih.gov.ORCID http://orcid.org/0000-0002-7828-5486
Yu Zhang *Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Beibei Ru *Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3897-7733
Yuan YangLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Trang VuCancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Rohit PaulOffice of the Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Amer MirzaXOMA Biotechnology, Emeryville, CA, USA.
Grégoire Altan-BonnetLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-7283-3162
Lingrui LiuDepartment of Health Policy and Management, School of Public Health, Yale University, New Haven, CT, USA.
Eytan RuppinCancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Lalage WakefieldLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kai W WucherpfennigDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. kai_wucherpfennig@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-1829-302X
National Institutes of Health · USAscendis Pharma (Denmark) · DKHarvard University · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Transcriptional mechanisms and melanomaP01CA163222 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LEONARD Ira ZON · 2013 to 2026
$25.3M
Understanding and Overcoming T cell Immunosuppression in GlioblastomaP01CA236749 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI E. Antonio Chiocca · 2020 to 2026
$19.5M
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D PathwayR01CA238039 · NCI · DANA-FARBER CANCER INST · PI Kai W Wucherpfennig · 2019 to 2026
$4.2M
Data-driven inference of regulators for cytokine-mediated tumor killingZIABC011889 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JIANG, PENG · 2019 to 2025
$4.1M
Yale Scholars in Implementation Science (YSIS)K12HL138037 · NHLBI · YALE UNIVERSITY · PI SHARIFI, MAHNOOSH · 2017 to 2021
$3.0M
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast CancerR01CA251599 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2020 to 2024
$2.4M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011889NCATS NIH HHS UL1 TR001863NCI NIH HHS P01 CA163222NCI NIH HHS P01 CA236749NCI NIH HHS R01 CA238039NCI NIH HHS R01 CA251599NHLBI NIH HHS K12 HL138037U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) Intramural Research BudgetU.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) K12HL138037
6 · The paper itself

Abstract

Cytokines are critical for intercellular communication in human health and disease, but the investigation of cytokine signaling activity has remained challenging due to the short half-lives of cytokines and the complexity/redundancy of cytokine functions. To address these challenges, we developed the Cytokine Signaling Analyzer (CytoSig; https://cytosig.ccr.cancer.gov/ ), providing both a database of target genes modulated by cytokines and a predictive model of cytokine signaling cascades from transcriptomic profiles. We collected 20,591 transcriptome profiles for human cytokine, chemokine and growth factor responses. This atlas of transcriptional patterns induced by cytokines enabled the reliable prediction of signaling activities in distinct cell populations in infectious diseases, chronic inflammation and cancer using bulk and single-cell transcriptomic data. CytoSig revealed previously unidentified roles of many cytokines, such as BMP6 as an anti-inflammatory factor, and identified candidate therapeutic targets in human inflammatory diseases, such as CXCL8 for severe coronavirus disease 2019.

Indexed as

Databases, ProteinSARS-CoV-2COVID-19CytokinesGene Expression RegulationHumansSignal TransductionCytokines

Identifiers

PMID34594031
PMCPMC8493809
OpenAlexW3202418805

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.